An interventional study of Sodium propionate and Sodium Chloride in Diabetes Mellitus, sponsored by Imperial College London. Terminated at 3 sites in United Kingdom. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-18.
Sponsored by Imperial College London · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Diabetes Mellitus by Imperial College London — 2 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · Imperial College London.
Among the 22 studies in Diabetes Mellitus by Imperial College London, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2013, is one of 11 with no phase, and was the 6th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 22 studies in Diabetes Mellitus by Imperial College London are open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18–70
By country, each count listing its studies:
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 26 across the 15 interventional studies, 916 across the 7 observational. Of the 13 that completed or were terminated, 12 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
2 of the studies in Diabetes Mellitus by Imperial College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06463483Imperial College LondonAutomated Insulin Delivery in Adults With Advanced Kidney Disease | 2026-12-30 |
| NCT06782568Imperial College LondonAvoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Diabetes Mellitus by Imperial College London, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of these studies is to firstly determine the pharmacokinetic profile of orally administered enteric coated sodium propionate. Subsequently, the most efficacious dose at improving glucose tolerance following an oral glucose challenge will be determined. The investigators will then determine the mechanism of action of propionate, whether it acts by altering beta cell function directly or by augmenting the incretin effect or both
The NHS spends £1M per hour, 10% of its yearly budget, treating diabetes. In the UK cases of diabetes are expected to top 4 million by 2025. There is an urgent need for new therapies. The short chain fatty acid propionate is a natural substance produced by digestion of fermentable carbohydrates. Preclinical and early human data demonstrate it improves pancreatic function and glucose control. The investigators aim to conduct proof of principle studies to determine if oral delivery of propionate improves glucose control in patients at risk of developing diabetes.
Inclusion Criteria:
Study 1: Healthy men and women aged between 18 and 70 years with between 20-25 kg/m2 and with normal fasting blood glucose (below5.5mmol/l and less than 5.7% will be eligible to volunteer.
Study 2: As for Study 1. Study 3: Cohort 1: Volunteers aged between 30 to 70 with a BMI between 25-35 kg/m2 who do not have impaired fasting glucose and have HbA1c below 5.7%.
Cohort 2: Volunteers aged between 30 to 70 years with a BMI between 25-35 kg/m2 who have impaired fasting glucose (between 5.5-7mmol/l) and HbA1C between 5.7% and 6.5%,
Exclusion Criteria:• Type 1 or Type 2 Diabetes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
Dietary Supplement: Sodium Chloride · Procedure: Oral glucose tolerance test · Procedure: Intravenous glucose tolerance test.
Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
Dietary Supplement: Sodium propionate · Procedure: Oral glucose tolerance test · Procedure: Intravenous glucose tolerance test.
Sodium propionate capsule or tablet
Placebo capsule or tablet
Propionate CMax
Study 1: Peak plasma concentration of propionate. Dose ranging and pharmacokinetic profile of propionate by Mass spectrometry has been measured at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h (the mean below was estimated first per patient (across all the above time points) and then per arm across the 6 patients)
Time frame: hours (up to 8hrs)
Total Amount of Insulin Stimulated by Propionate Per Unit Time (Incremental Area Under the Curve)
Study 3: Participants will undergo a frequently sampled oral glucose tolerance test (OGTT) to detect changes in insulin sensitivity and beta cell function. Where maximum insulin increments during a glucose tolerance test will be reported on a scale 0 to 1000 where 0 is the lowest and 1000 is the highest outcome
Time frame: 10 minutes
Insulinogenic Index (Change in Insulin Divided by the Change in Glucose Over the First 30 Minutes of the Test)
Study 2: insulinogenic index. Oral glucose tolerance dose finding was measured with commercially available kits (the mean below was estimated per arm across the 6 patients)
Time frame: 30mins
Insulin Levels in Response to the Absorption of Proprionate (Total Insulin Across All Time Points)
Plasma insulin has been measured using commercially available kits at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h (the mean below was estimated first per patient (across all the above time points) and then per arm across the 6 patients)
Time frame: hours (up to 8 hours)
Recruitment started March 2013 and ended August 2016. The study was based at the clinical research facility at Imperial College Health Care Trust but never completed. Only 6 where recriuted and completed. The target was 12
| Milestone | Sodium Chloride Pill | Sodium Propionate Pill |
|---|---|---|
| Started | 3 | 3 |
| Completed | 3 | 3 |
| Not completed | 0 | 0 |
| Milestone | Sodium Chloride Pill | Sodium Propionate Pill |
|---|---|---|
| Started | 3 | 3 |
| Completed | 3 | 3 |
| Not completed | 0 | 0 |
| Milestone | Sodium Chloride Pill | Sodium Propionate Pill |
|---|---|---|
| Started | 3 | 3 |
| Completed | 3 | 3 |
| Not completed | 0 | 0 |
Study 1: Peak plasma concentration of propionate. Dose ranging and pharmacokinetic profile of propionate by Mass spectrometry has been measured at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h (the mean below was estimated first per patient (across all the above time points) and then per arm across the 6 patients)
| mmol/l | Sodium Chloride Capsule | Sodium Propionate Capsule |
|---|---|---|
| Propionate CMax | 7.2 ± 0.26 | 7.79 ± 0.25 |
Study 3: Participants will undergo a frequently sampled oral glucose tolerance test (OGTT) to detect changes in insulin sensitivity and beta cell function. Where maximum insulin increments during a glucose tolerance test will be reported on a scale 0 to 1000 where 0 is the lowest and 1000 is the highest outcome
| uM/min | Sodium Chloride Capsule | Sodium Propionate Capsule |
|---|---|---|
| Total Amount of Insulin Stimulated by Propionate Per Unit Time (Incremental Area Under the Curve) | 677.5 ± 24 | 678 ± 25 |
Study 2: insulinogenic index. Oral glucose tolerance dose finding was measured with commercially available kits (the mean below was estimated per arm across the 6 patients)
| index | Sodium Chloride Capsule | Sodium Propionate Capsule |
|---|---|---|
| Insulinogenic Index (Change in Insulin Divided by the Change in Glucose Over the First 30 Minutes of the Test) | 30.2 ± 12 | 31 ± 12.5 |
Plasma insulin has been measured using commercially available kits at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h (the mean below was estimated first per patient (across all the above time points) and then per arm across the 6 patients)
| uM/l | Sodium Chloride Capsule | Sodium Propionate Capsule |
|---|---|---|
| Insulin Levels in Response to the Absorption of Proprionate (Total Insulin Across All Time Points) | 8142 (6809 to 9737) | 8316 (7148 to 9674) |
Collected over 1 week. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sodium Chloride Pill | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Sodium Propionate Pill | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
only 6 where recriuted and completed
| Age, Categorical(Participants) | Sodium Chloride | Sodium Propionate | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 6 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Sodium Chloride | Sodium Propionate | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Sodium Chloride | Sodium Propionate | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 3 | 6 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Sodium Chloride | Sodium Propionate | Total |
|---|---|---|---|
| United Kingdom | 3 | 3 | 6 |
| Propionate(micromol/l) | Sodium Chloride | Sodium Propionate | Total |
|---|---|---|---|
| Mean | 0.05 ± 0.05 | 0.05 ± 0.05 | 0.05 ± 0.05 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2013 to primary completion in Aug 2019, 79 months.
Results were first posted in Jun 2025, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium propionate